The US Food and Drug Administration reveals it holds out hope for establishing lawful use of hemp ingredients in non-drug products subject to its regulatory oversight by launching another program intended to gather data.
The Cannabis-Derived Products Data Acceleration Plan launched in October, however, could reach the same conclusion the agency has found in its more-than two-year search for data and other information on the use of ingredients from the cannabis plant in dietary supplements,
While the FDA includes the term cannabis in the program title, the ingredients used in products it needs information on would be cannabinoids derived or extracted from hemp, defined as any part of the cannabis plant containing no more than 0